The concept of early combination therapy for type 2 diabetes management and evidence-based progress on basal insulin/glucagon-like peptide-1 receptor agonist fixed-ratio combinations
10.3760/cma.j.cn311282-20250220-00084
- VernacularTitle:2型糖尿病早期联合治疗理念及基础胰岛素/胰升糖素样肽1受体激动剂固定比例复方制剂循证进展
- Author:
Jie MIN
1
;
Lulu CHEN
1
Author Information
1. 华中科技大学同济医学院附属协和医院内分泌科，武汉 430022
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus, type 2;
Early combination therapy;
Basal insulin;
Glucagon-like peptide-1 receptor agonists;
Fixed-ratio combinations
- From:
Chinese Journal of Endocrinology and Metabolism
2025;41(6):527-532
- CountryChina
- Language:Chinese
-
Abstract:
With a growing understanding of the pathophysiological mechanisms underlying type 2 diabetes mellitus and the continuous accumulation of evidence from clinical studies, the concept of early combination therapy has been increasingly integrated into clinical diabetes management. Compared with traditional sequential treatment, early combination therapy can more comprehensively address the multiple pathophysiological mechanisms of type 2 diabetes mellitus. This approach not only provides earlier and more durable glycemic control, but also helps delay the onset and progression of diabetes-related complications. This review summarizes the comprehensive clinical benefits and therapeutic advances of early combination therapy, with a particular focus on the evidence - based progress of basal insulin/glucagon-like peptide-1(GLP-1) receptor agonist fixed-ratio combinations as an optimized treatment strategy for type 2 diabetes mellitus.
